A biotech announcement may describe a trial as “positive”, but that word cannot tell the whole story. For an investor, the useful task is to identify exactly what the study established and which questions remain open.

Start with the question the trial planned to answer

An endpoint is a defined outcome the study measures. Primary endpoints establish whether the study meets its main objective; secondary endpoints add information, while exploratory findings can suggest questions for future research. The FDA’s guidance on multiple endpoints explains why testing many outcomes needs statistical safeguards against false positive conclusions.

Check whether the headline refers to the planned main outcome, a secondary measure or a subgroup selected after looking at the data. These findings can carry different evidential weight. Also check the population, comparison group and measurement date. A result in one setting cannot automatically answer a different question.

Separate the size of the effect from its certainty

Hypothetical example: 30 of 100 participants meet a predefined response measure in one group, compared with 20 of 100 in the other. That is a 10 percentage point difference, or a 50% relative increase. Both descriptions are arithmetically correct; neither alone establishes statistical significance or clinical importance.

Statistical significance means a result has crossed a specified statistical threshold under the analysis’s assumptions. It does not measure how much the benefit matters to patients. Look for the estimated difference and its confidence interval, which communicates uncertainty around that estimate. The CDC explains this distinction.

Clinical importance concerns whether the improvement is meaningful in context. For patient-reported outcomes, the FDA specifically cautions against relying on statistical significance alone. The burden of treatment and safety findings also matter.

Read the whole result

Check how many participants contributed data, who stopped treatment, and whether important results are still missing. Review adverse events alongside benefits and consider the length of follow-up. The FDA’s clinical-research overview explains why study design and continued safety assessment matter.

Our reading framework is to compare the announcement with the study protocol, analysis plan and full results when available. A short announcement may leave material questions unanswered; a favourable headline cannot, by itself, establish an investment’s value.

Educational information only. It does not take account of your objectives, financial situation or needs. This article does not provide medical advice.